Xenogeneic bone matrix immune risk assessment using GGTA1 knockout mice.

Area of Science:

• Biomaterials Science
• Immunology
• Regenerative Medicine

Background:

• Human donor bone scarcity necessitates alternatives like xenografts.
• Xenografts pose immune risks due to alpha-Gal antigens, limiting clinical use.
• Assessing xenograft immune risk and reliable animal models are crucial.

Purpose of the Study:

• To evaluate the immune response to two types of bone substitutes (T1 and T2) in GGTA1 knockout mice.
• To determine if reduced alpha-Gal antigen content in T2 impacts immunogenicity.
• To validate GGTA1 knockout mice as a model for assessing xenograft biomaterials.

Main Methods:

• Quantified alpha-Gal antigen levels in T1 and T2 bone substitutes in vitro using ELISA.
• Implanted T1 and T2 bone substitutes subcutaneously into GGTA1 knockout mice for 12 weeks.
• Assessed serum antibody levels (total IgG, IgM, IgA, anti-alpha-Gal IgG), inflammatory cytokines (IL-4, IL-12P70, IL-10), splenic lymphocyte surface molecules, and performed histological analysis.

Main Results:

• T2 bone substitutes had significantly lower alpha-Gal antigen content than T1.
• T1 group showed significantly higher total and anti-alpha-Gal antibody levels and inflammatory cytokines compared to T2 and control groups.
• T2 group exhibited minimal immune response, comparable to the control group, with lighter inflammation observed histologically.

Conclusions:

• Antigen reduction effectively decreased the immunogenicity of xenograft bone substitutes (T2).
• T2 bone substitutes demonstrate potential as safe and effective bone healing materials.
• GGTA1 knockout mice serve as a valuable tool for evaluating the immune risk of animal-derived biomaterials.